Skip to content

Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970
46.53 +0.12 +0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 46.00 -0.88%
After-hours 46.53 0.00%
61.1533.6346.532026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ELVN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +48.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 14.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -27.0% Better than 14%
Return on invested capital -31.1% Better than 10%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -22.2% Better than 28%
6-month return 12.0% Better than 75%
12-month return (ex latest month) 90.9% Better than 94%
Distance below 52-week high 25.3% Better than 50%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 28.7x Better than 99%
Debt to assets 0.1% Better than 99%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 60.9% Better than 72%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.65%
1M +12.80%
3M -21.03%
6M +11.16%
YTD +202.14%
1Y +118.76%
3Y +341.46%
5Y +252.50%

Key statistics

Price & volume

Prev close
46.41
Open
46.05
Day range
45.64 - 47.83
Avg price
46.59
Volume
933.56K
Turnover
43.50M
Amplitude
4.72%
52-week range
14.79 - 62.32

Valuation

P/E
-25.43
P/E (TTM)
-27.53
P/B
3.90
EPS
-1.83
Net profit
-134.68M
Net assets
876.96M

Share structure

Market cap
3.42B
Float cap
3.02B
Shares out
73.60M
Float shares
64.84M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 67% of range
14.79 62.32

25.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-9.65M net over the window

Short interest

Shares short
10.29M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Enliven Therapeutics (ELVN)?

Enliven Therapeutics last traded at 46.53. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Enliven Therapeutics's market cap?

About 3.42B.

What is the P/E ratio of Enliven Therapeutics?

The trailing twelve-month P/E is -27.53. The Valuation tab shows it against the stock's own five-year range.

Does Enliven Therapeutics pay a dividend?

Enliven Therapeutics does not currently pay a regular dividend.

Is Enliven Therapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 74.88, which implies 60.9% upside from the current price. This is not investment advice.

What is Enliven Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Enliven Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Enliven Therapeutics discussion 0 comments

Add a comment